ImmunityBio, Inc. announced new data showing that the company's Memory Cytokine-Enriched Natural Killer cells (M-ceNK) may provide benefit to patients with small cell lung cancer and patients with other types of neuroendocrine tumors. Findings from the study titled " Characterization of the anti-tumor activity of memory cytokine enriched NK cells (M-ceNK") against tumors with neuroendocrine features" were presented by Kristen Fousek, Ph.D., Research Fellow with the Center for Immuno-Oncology of the National Institutes of Health'sNational Cancer Institute (NCI) in a poster session (Abstract #358) at the annual meeting of the Society for Immunotherapy of Cancer (SITC) in San Diego, November 4, 2023. In the new study, the killing capacity of M-ceNK cells was assessed in four SCLC cell lines representing the major molecular subtypes.

(M-ceNK cells are a unique set of white blood cells (lymphocytes) that are first collected from individual patients (autologous cells) then differentiated into the specialized NK cells with enhanced anti-cancer function by brief pre-activation with interleukin-12 (IL-12), IL-15, and IL-18. The safety and preliminary efficacy of M-ceNK cells in locally advanced or metastatic solid tumors are currently being assessed in the Phase 1 clinical trial, QUILT-3.076, which is actively enrolling patients at this time (NCT04898543). Safety and efficacy of these investigational agents have not been established by any Health Authority or Agency, including the FDA.